Boston Scientific (BSX) Surpasses Market Returns: Some Facts Worth Knowing

Group 1: Stock Performance - Boston Scientific (BSX) stock increased by 1.05% to $102.36, outperforming the S&P 500's gain of 0.96% for the day [1] - Over the past month, BSX stock has decreased by 3.06%, underperforming the Medical sector's loss of 0.85% and the S&P 500's gain of 0.5% [1] Group 2: Earnings Expectations - Analysts expect Boston Scientific to report an EPS of $0.72, reflecting a 16.13% increase from the prior-year quarter [2] - Revenue is forecasted to be $4.89 billion, indicating an 18.69% growth compared to the same quarter last year [2] Group 3: Fiscal Year Projections - For the entire fiscal year, earnings are projected at $2.91 per share and revenue at $19.5 billion, representing increases of 15.94% and 16.42% respectively from the previous year [3] Group 4: Analyst Estimates and Market Sentiment - Recent changes in analyst estimates for Boston Scientific are important as they reflect the evolving business landscape, with positive revisions indicating analyst optimism [3] - The Zacks Rank system, which incorporates estimate changes, currently ranks Boston Scientific at 3 (Hold) [5] Group 5: Valuation Metrics - Boston Scientific has a Forward P/E ratio of 34.75, which is higher than the industry average of 18.05 [6] - The company also has a PEG ratio of 2.62, compared to the Medical - Products industry's average PEG ratio of 2.24 [7] Group 6: Industry Context - The Medical - Products industry, part of the Medical sector, has a Zacks Industry Rank of 164, placing it in the bottom 34% of over 250 industries [7] - The Zacks Industry Rank indicates that the top 50% of rated industries outperform the bottom half by a factor of 2 to 1 [8]